NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The nccn guidelines have been updated to include a recommendation for taletrectinib. This recommendation is specifically for a subtype of non-small cell lung cancer characterized by the presence of the ros1 mutation. Taletrectinib is now recommended for patients with this particular subtype of the disease.